DC-KENUP-FOUNDATION
15.11.2020 16:02:06 CET | Business Wire | Press release
On the occasion of the Annual Meeting of the American Society of Tropical Medicine and Hygiene approximately 4,900 global health professionals representing academia, government, and the private sector were informed about the latest investment of the EU Malaria Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005124/en/
The EU Malaria Fund is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. The EU Malaria Fund has been initiated by kENUP Foundation and is managed by a General Partner under the supervision of Investitionsbank Berlin.
On November 13, 2020, Sanaria received €12.9M for the development of two malaria vaccines, one malaria prophylactic, as well as an initial proof-of-concept for an oral SARS-CoV-2 vaccine.
Sanaria’s PfSPZ Vaccine is a radiation-attenuated whole-organism vaccine, meaning it is a weakened form of the parasite that causes malaria. PfSPZ Vaccine elicits an immunological response in the body against the malaria pathogen, without the individual getting sick. This results in robust and durable protection. On the verge of Phase III clinical trials, PfSPZ Vaccine is positioned to be the world’s first malaria vaccine to receive marketing authorization. Sanaria’s second generation vaccine, Sanaria PfSPZ-CVac (Chemoprophylaxis Vaccine), focuses on increased potency and decreased costs. The funding also advances the research and development of human monoclonal antibodies from multiple candidates based on potency and manufacturability in order to provide immediate short-term protection against malaria. Finally, a portion of the funding will be used to advance OraCOV, an oral, self-administered vaccine candidate against COVID-19, based on Sanaria’s work in malaria.
Dr. Stephen L. Hoffman, Sanaria’s founder and CEO said, “We applaud the EU Malaria Fund for addressing this critical funding gap and we are grateful and honored to be the recipient of this investment.”
“We wholeheartedly welcome the efforts of Sanaria, who for many years have been at the forefront of innovation and are bringing novel concepts to the table potentially reducing the unacceptable burden of malaria,” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme at the online signature event.
Holm Keller, Co-Managing Director of EUMF and Chairman of kENUP Foundation said: “Sanaria has developed one of the most advanced malaria vaccine candidates worldwide. We hope that this investment will help towards the eradication of malaria “.
More information can be found at https://www.controlmalaria.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20201115005124/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom